drugset / Trial / NCT07108998
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 2 study of Epcoritamab as a consolidation therapy for 2nd generation BTKi +/- Obinutuzumab in CLL/SLL patients or patients with variants of this.
Timeline
- Start
- 2025-08-22
- Primary completion
- 2027-07-01
- Completion
- 2029-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epcoritamab | Monoclonal antibody | 24 mg | Subcutaneous |
| Subject | Epcoritamab | Monoclonal antibody | 48 mg | Subcutaneous |